home / stock / nvsef / nvsef short
Short Information | Novartis Ag Basel Akt (OTCMKTS:NVSEF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 100,246 |
Total Actual Volume | 164,970 |
Short Trends | |
---|---|
Cover Days | 11 |
Short Days | 9 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 5,012 |
Average Short Percentage | 45.78% |
Is there a NVSEF Short Squeeze or Breakout about to happen?
See the NVSEF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-15-2024 | $0 | $105.17 | $0 | $0 | 20 | 11 | 55% |
07-12-2024 | $0 | $105.17 | $0 | $0 | 86 | 2 | 2.33% |
07-11-2024 | $106.21 | $105.17 | $106.21 | $105.15 | 35,900 | 35,900 | 100% |
07-02-2024 | $103.76 | $106.9 | $106.9 | $103.76 | 4,206 | 1,242 | 29.53% |
06-28-2024 | $104 | $104 | $104 | $104 | 100 | 100 | 100% |
06-26-2024 | $106.55 | $102.69 | $106.55 | $102.69 | 17,848 | 23 | 0.13% |
06-25-2024 | $0 | $106.51 | $0 | $0 | 5,472 | 922 | 16.85% |
06-24-2024 | $106.1 | $106.51 | $107.0849 | $106 | 2,109 | 553 | 26.22% |
06-20-2024 | $108.5 | $102.43 | $108.5 | $102.43 | 5,320 | 287 | 5.39% |
06-17-2024 | $103 | $104.085 | $104.4775 | $103 | 21,172 | 328 | 1.55% |
06-12-2024 | $101.29 | $101.29 | $101.29 | $101.29 | 481 | 336 | 69.85% |
06-11-2024 | $0 | $102 | $0 | $0 | 12,501 | 12,500 | 99.99% |
06-07-2024 | $0 | $102 | $0 | $0 | 15,010 | 15,000 | 99.93% |
06-06-2024 | $0 | $102 | $0 | $0 | 10,030 | 10,030 | 100% |
06-05-2024 | $102 | $102 | $102 | $102 | 23,017 | 22,500 | 97.75% |
06-03-2024 | $100 | $100 | $100 | $100 | 8,085 | 54 | 0.67% |
05-31-2024 | $97.97 | $97.97 | $97.97 | $97.97 | 160 | 50 | 31.25% |
05-29-2024 | $98.3 | $98 | $99.84 | $98 | 2,870 | 100 | 3.48% |
05-28-2024 | $98 | $98 | $98 | $98 | 158 | 8 | 5.06% |
05-22-2024 | $103.75 | $103 | $103.75 | $103 | 425 | 300 | 70.59% |
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...